Bli medlem
Bli medlem

Du är här


Eckert & Ziegler BEBIG: First Quarter Results 2014 Published

Seneffe - Belgium, May 6, 2014
, Eckert&Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB)
has announced today its Interim Statement for the first quarter 2014. The
report including a selection of consolidated key figures for the 3 months
ending March 31, 2014 can be downloaded at: >Investor Relations>Financial Reports

At EUR 6.5 million, sales in the first quarter of 2014 were considerably
higher compared to EUR 5.5 million in the prior year. The increase in sales
is exclusively a result of the recently acquired business in the US.

Eckert&Ziegler BEBIG
...Contributing to saving lives!

Eckert&Ziegler BEBIG, incorporated in 1996, is a European-based company active
in the medical device segment of the health care industry.

Eckert&Ziegler BEBIG's core business is the treatment of cancer using
brachytherapy, a special form of radiation therapy.

Eckert&Ziegler BEBIG is a leader in brachytherapy in Europe. The company
headquarters are in Belgium, with a production facility in both Germany and
the USA and subsidiaries throughout Europe as well as in India and Brazil. In
addition, Eckert&Ziegler BEBIG has a worldwide network of distributors and
agents to support the international marketing of its product line.

The company's products and equipment are intended for use by oncologists,
radiologists, urologists, and medical physicists. Eckert&Ziegler BEBIG
employs more than 200 people. The company has been listed on the NYSE
Euronext Brussels stock exchange since April 1997 (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB).

BEBIG s.a.
Investor Relations
Tel.: +32 (0) 64 520 808


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert&Ziegler BEBIG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.